Phase 2 data published in 2023 reported mean body-weight reductions of up to 24.2% at 48 weeks on the highest dose tier (Jastreboff et al., NEJM 2023)
L-Carnitine supplementation: a new paradigm for its role in exercise
H tr lm sng v u mu da, ci thin cc vng da b sm, nm, tn nhang Ngoi qu trnh t sn xut Glutathione ca c th, chng ta vn cn b sung thm hot cht ny t ngun bn ngoi vo c th
But where can one find such a precious resource
However, we also offer alternative treatment modalities for patients who are averse to getting Botox injections
The Core GLP-1 Mechanism GLP-1 Pathway Simplified Meal Intake Intestinal L-cells release GLP-1 GLP-1 binds GLP-1 receptors cAMP signaling Activation of PKA + PI3K/Akt pathways Multiple metabolic benefits Practical Clinical Effects In the Pancreas Insulin secretion from -cells Glucagon secretion from -cells Preservation of -cell mass Reduced -cell apoptosis In the Brain Appetite suppression Satiety enhancement Reduced food cravings In the Gastrointestinal Tract Delayed gastric emptying Reduced postprandial glucose spikes In Peripheral Tissues Improved glucose uptake Enhanced insulin sensitivity Reduced hepatic gluconeogenesis Evolution of GLP-1 Therapy: Historical Milestones Current Era Emergence of: Oral GLP-1 drugs Dual agonists Triple agonists Small-molecule GLP-1 therapies Current GLP-1 Agents Short-Acting Exenatide Lixisenatide Long Acting Liraglutide Dulaglutide Semaglutide Oral GLP-1 Oral semaglutide Orforglipron (new generation oral small-molecule GLP-1RA) Dual Agonists Tirzepatide (GLP-1 + GIP) Triple Agonists Retatrutide (GLP-1 + GIP + glucagon receptor) These newer agents are redefining obesity medicine and cardiometabolic care
